In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - BCC-014-DFMO
Protocol Summary
- Protocol No
- BCC-014-DFMO
- Principal Investigator
- Nathan Schloemer
- Phase
- II
- Title
- NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
- Associated Disease(s)
-
Early Phase Trials (Phase I and II)
- Description (Summary)
- The purpose of this research study is to test an investigational drug (DFMO) for Neuroblastoma that is in remission. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to keep your tumor in
remission and will also look at the safety and tolerability* of DFMO.
*Tolerability means how well you or your body can tolerate; or put up with the possible side effects and/or symptoms you may have from taking the DFMO. DFMO was shown to be effective in inhibiting tumor growth in adult colon cancers. DFMO has been tested in several adult and pediatric clinical trials. Laboratory testing in neuroblastoma suggests that this drug may be effective in preventing relapse of this disease.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
